Introduction: Why “Beyond E. coli” Matters For decades, E. coli has been the undisputed workhorse of microbial biomanufacturing. From recombinant insulin in the 1980s to a vast array of enzymes, antibody fragments, and research proteins, E. coli has set the standard for scalability, cost efficiency, and genetic tractability. Yet as the biologics landscape becomes increasingly complex—spanning full-length antibodies, […]
Tag: CDMO Manufacturing
Overcoming Endotoxin Challenges in Therapeutic Phage Manufacturing: A CDMO Perspective
Endotoxin removal is one of the most persistent bottlenecks in bringing therapeutic bacteriophages to market. Produced by the outer membrane of Gram-negative bacteria, endotoxins (lipopolysaccharides, or LPS) can trigger severe immune reactions in patients if not reduced to ultra-low levels. For a Contract Development and Manufacturing Organization (CDMO), especially one producing phage therapies at GMP […]